Healthequity

What Healthequity does

Healthequity S.C.R., S.A. is a privately held Spanish venture capital company (Sociedad de Capital Riesgo) incorporated under Spanish law in 2014 and headquartered in Barcelona at Passeig de la Bonanova, 47 (registered office) and Paseo de Gracia, 54 (contact office). The firm specializes in early-stage investments in the health sector — specifically medical devices, biotechnology, and healthcare services — and operates within the regulatory framework of Ley 22/2014 de Entidades de Capital Riesgo. Its portfolio focus is therefore the Spanish and broader European health-innovation ecosystem, with shareholders that include corporate strategics (Corporación Químico-Farmacéutica Esteve), institutional investors (Innvierte Economía Sostenible, Crèdit Andorrà Select Private Equity), and family/holding entities (Jormavi, S.L.), all under the controlling ownership of parent company GRUP MED CORPORATIU, S.A.U., represented on the board by Dr. Jaume Aubia Marimon.

The firm's business model is that of a regulated closed-end venture capital vehicle: it raises and pools investor capital, deploys it into qualifying healthcare investments, and ultimately returns proceeds to shareholders. Capital activity is disclosed through ordinary and extraordinary shareholder meetings, with the last recorded capital reduction occurring on 9 February 2023, which brought share capital to €9,339,942 (represented by 9,339,942 shares of €1 nominal value). At 11–50 employees, the organization is lean and has no disclosed product, software platform, or pricing model; its sole "product" is fund management. The June 2025 shareholder agenda includes a formal debate on extending the company's duration, and recurring annual meetings continue at least through 11 June 2026, indicating active but maturity-bound operations.

From an operating perspective, the entity does not appear to offer discrete products or technology platforms, has no disclosed app, API, or SDK, and operates solely through private shareholder networks and direct investor relationships. Pricing, marketing channels, distribution channels, certifications, patents, trademark filings, and named portfolio-company investments are not disclosed in the source material, and no revenue figure has been publicly reported. Recent strategic activity has skewed toward capital restructuring (shareholder-driven capital reductions in 2022 and 2023) and shareholder composition changes (entry/exit of EVENTURES, ESTEVE, JORMAVI, and others), consistent with a maturing vehicle rather than an expanding platform.

Name

Healthequity

Legal name

HEALTHEQUITY S.C.R., S.A.

Website

https://healthequity.es

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Healthequity S.C.R., S.A. is a privately held, Barcelona-based Spanish venture capital company (regulated under Ley 22/2014) that invests early-stage capital into medical devices, biotechnology, and healthcare services companies, controlled by parent GRUP MED CORPORATIU, S.A.U.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Finance and Insurance (52)

SIC

Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

akta.pro secondary industries

Joint Venture CVC / Consortium Funds (Multi-corporate) (FSANAHAE), Corporate LP Programs (Corporate as LP in VC/PE funds) (FSANAHAH)

Keywords

• Venture capital
• Healthcare investments
• Biotech investments
• Medical devices investment
• Health sector investing

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Core offering

Healthequity S.C.R., S.A. is a Spanish venture capital company (Sociedad de Capital Riesgo) that invests capital in early-stage companies in the healthcare sector, including medical devices, biotechnology, and healthcare services. The firm operates under Spanish Law 22/2014 on Venture Capital Entities and deploys shareholder-contributed capital into healthcare and life sciences ventures.

Product overview

Healthequity is a Spanish Risk Capital Company (S.C.R., S.A.) focused on healthcare and life sciences investments. The company operates as a private equity/venture capital firm that invests in health-related companies, as evidenced by references to investment requirements verification in shareholder meetings and connection to invivo.capital for additional investment information. The company does not appear to offer distinct software products or technology platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare Venture Capital Investment

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights2 records

Direct peers

• Invivo Capital: Invivo Capital is the directly related Spanish healthcare venture capital platform referenced from Healthequity's own website (healthequity.es links to invivo.capital for further information). They share GP-adjacent branding, a focus on early-stage Spanish/European life sciences, and operate within the same family of S.C.R. vehicles, making them the most directly comparable peer.
• Ysios Capital: Ysios Capital is a leading Spanish/European venture capital firm exclusively dedicated to life sciences (biotech, medtech, diagnostics). Both Healthequity and Ysios are Spain-rooted healthcare-only VCs targeting similar early-stage European companies, giving them high comparability in mandate, geography, and ticket size.
• Asabys Partners: Asabys Partners is a Barcelona-based venture capital firm dedicated to healthcare investments across medtech, digital health, and therapeutics. Like Healthequity, it is headquartered in Barcelona, focuses on early-stage Spanish/European healthcare, and competes directly for both regional deal flow and Spanish family-office LP capital.
• Caixa Capital Risc: Caixa Capital Risc is the venture capital arm of "la Caixa" and invests from Spain into early-stage companies including healthcare. It is a relevant peer because, like Healthequity, it is a regulated Spanish VC entity engaging Spanish LPs and targeting similar early-stage health/biotech opportunities in the Iberian ecosystem.
• Inveready Asset Management: Inveready is a Spanish alternative asset manager with several S.C.R./SICAV vehicles investing in early-stage Spanish companies including biotech and healthcare-adjacent sectors. It is comparable to Healthequity in domicile, regulatory vehicle type, and stage focus, competing for many of the same portfolio companies and regional LP relationships.
• Kurma Partners: Kurma Partners is a European venture capital firm focused on healthcare and life sciences, with links to the Idinvest/AXA group. Like Healthequity, it deploys dedicated capital into European early-stage therapeutics and medtech from a regulated fund vehicle, making business model and target assets closely aligned.

Broad incumbents

• Forbion: Forbion is an established European life-sciences venture capital firm managing multiple funds with multi-hundred-million-euro AUM. It shares Healthequity's disease-agnostic healthcare focus but is significantly larger and more global; it represents the incumbent benchmark for Spanish healthcare founders when choosing between regional and pan-European investors.
• Sofinnova Partners: Sofinnova is a long-established European venture capital firm with healthcare as one of its core franchises (Sofinnova Crossover Fund and Sofinnova MD Start). It competes with Healthequity for European healthcare deals but operates at a meaningfully larger AUM and longer track record, positioning it as a broad-incumbent comparable.
• Novo Holdings (Novo Seeds): Novo Holdings is a Danish-owned holding and venture investor with Novo Seeds dedicated to early-stage biotech. It is comparable to Healthequity in stage and asset class (European life-sciences venture investing) but dwarfs it in AUM and LP backing, functioning as a broad-incumbent regional peer.
• Andera Partners: Andera Partners (formerly Edmond de Rothschild Investment Partners) is a Paris-based private investment firm with dedicated life-sciences venture activity. It shares Healthequity's European early-stage healthcare mandate but operates with materially greater scale and team size, making it a useful broad-incumbent reference point for valuation and positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/healthequity-scr

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healthequity